Recent Advances in the Development of Adenovirus-Vectored Vaccines for Parasitic Infections

Pharmaceuticals (Basel). 2023 Feb 22;16(3):334. doi: 10.3390/ph16030334.

Abstract

Vaccines against parasites have lagged centuries behind those against viral and bacterial infections, despite the devastating morbidity and widespread effects of parasitic diseases across the globe. One of the greatest hurdles to parasite vaccine development has been the lack of vaccine strategies able to elicit the complex and multifaceted immune responses needed to abrogate parasitic persistence. Viral vectors, especially adenovirus (AdV) vectors, have emerged as a potential solution for complex disease targets, including HIV, tuberculosis, and parasitic diseases, to name a few. AdVs are highly immunogenic and are uniquely able to drive CD8+ T cell responses, which are known to be correlates of immunity in infections with most protozoan and some helminthic parasites. This review presents recent developments in AdV-vectored vaccines targeting five major human parasitic diseases: malaria, Chagas disease, schistosomiasis, leishmaniasis, and toxoplasmosis. Many AdV-vectored vaccines have been developed for these diseases, utilizing a wide variety of vectors, antigens, and modes of delivery. AdV-vectored vaccines are a promising approach for the historically challenging target of human parasitic diseases.

Keywords: adenovirus vaccines; helminth; parasites; protozoa; vaccine vector.

Publication types

  • Review

Grants and funding

National Reference Centre for Parasitology, is supported by the Public Health Agency of Canada/National Microbiology Laboratory, the Foundation of the McGill University Health Centre, the Research Institute of the McGill University Health Centre, and the R. Howard Webster Foundation.